People Living with Atopic Dermatitis or Psoriasis
Atopic dermatitis and psoriasis are serious skin diseases that affect over 300 million people globally. Atopic dermatitis causes itchy, inflamed skin that can become blistered, while psoriasis is characterised by red, scaly plaques on the skin. For many patients, the treatments available do not work well and the diseases place a huge burden on patients, their families, and healthcare systems.
BIOMAP aims to shed new light on the underlying causes of both diseases, as well as the genetic and environmental factors that influence how a patient's disease will progress and how well they will respond to a given treatment.
We are doing this by studying in depth data and samples from more than 50,000 patients as well as healthy individuals. Ultimately, BIOMAP hopes to identify new sub-types of the diseases that will allow clinicians and patients to make better, more personalised and precise decisions on treatments.
Patient involvement
To ensure patients' views are integrated into the project, a Patient Board has been set up which complements the BIOMAP expertise and has been consulted from the beginning of BIOMAP. The representatives of the Patient Board give voice to the desires and needs of people with atopic dermatitis (AD) and Psoriasis (Pso) patients. This board consisting of six AD and Pso focused patient organisations and are working within and across Work Packages serving as an advisory resource to BIOMAP.
More information in our network section!
“BIOMAP is a European-wide programme that truly focus on patient needs.”
Lars F. Werner, CEO of the Danish Psoriasis Association / EUROPSO
“BIOMAP will bring together a wealth of existing and new data as well as world-renowned experts; this has the potential to unlock some major discoveries and lead to better treatments in inflammatory skin diseases, directly improving the quality of life of millions.”
Magali Redding, Founding CEO of Eczema Outreach Support
“BIOMAP will provide essential information and support to clinicians when deciding the best treatment option for a particular individual with a particular type of psoriasis or atopic eczema, thus improving the health outcome in individuals with these inflammatory skin conditions”
David Mc Mahon, CEO of the Irish Skin Foundation